June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
AUTOLOGOUS PLATELET RICH PLASMA THERAPY IN RESISTANT CORNEAL ULCERS
Author Affiliations & Notes
  • Yakup Aksoy
    Ophthalmology, Gülhane Military Medical Academy Haydarpasa Education Hospital, istanbul, Turkey
  • Uzeyir Erdem
    Ophthalmology, Gülhane Military Medical Faculty, Ankara, Turkey
  • Footnotes
    Commercial Relationships Yakup Aksoy, None; Uzeyir Erdem, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5230. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yakup Aksoy, Uzeyir Erdem; AUTOLOGOUS PLATELET RICH PLASMA THERAPY IN RESISTANT CORNEAL ULCERS. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5230.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To assess the results and the application procedures of the platelet rich plasma therapy which is a novel option in resistant corneal ulcers?

Methods: We performed limited debridement after harvesting adequate samples from the margin of the lesions for culture and HSV PCR in nine eyes of the eight corneal ulcer sterile patients who had a history of resistant corneal ulcer one or more year inconclusive trials of various therapies. After the debridement all eyes administered autologous platelet rich plasma (8 drops/day).

Results: Corneal ulcers of all cases were healed in about 4,3(±2,3) weeks. Visual acuity improvement was 4,1(±2,4) lines. In one case, epithelial defect relapsed after six months but, healed in 3 weeks again using the same protocol. we also applied wet PTK in 4 eyes after the treatment period.

Conclusions: We found that autologous platelet rich plasma therapy is effective in resistant corneal ulcers as an adjunctive therapy. Further investigations should be done in wider and different case series to prove its benefits in resistant corneal ulcers and also in different clinical applications.

Keywords: 479 cornea: clinical science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×